Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, July 12, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jeffrey Hung Maintained (ACAD) at Buy with Decreased Target to $28 on, Jul 12th, 2024
Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $30 to $28 on, Jul 12th, 2024.
Jeffrey has made no other calls on ACAD in the last 4 months.
There are 15 other peers that have a rating on ACAD. Out of the 15 peers that are also analyzing ACAD, 4 agree with Jeffrey's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $22 on, Friday, May 10th, 2024
- Paul Matteis of "Stifel" Maintained at Hold with Decreased Target to $21 on, Thursday, May 9th, 2024
- Uy Ear of "Mizuho" Maintained at Hold with Decreased Target to $21 on, Thursday, May 9th, 2024
- Jay Olson of "Oppenheimer" Maintained at Hold and Held Target at $19 on, Monday, May 6th, 2024
These are the ratings of the 11 analyists that currently disagree with Jeffrey
- Keith Tapper of "BMO Capital" Initiated at Buy and Held Target at $31 on, Thursday, June 27th, 2024
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $29 on, Tuesday, June 25th, 2024
- Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $28 on, Thursday, May 9th, 2024
- Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $30 on, Thursday, May 9th, 2024
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $27 on, Thursday, May 9th, 2024
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $37 on, Thursday, May 9th, 2024
- David Hoang of "Citigroup" Maintained at Strong Buy and Held Target at $30 on, Thursday, May 9th, 2024
- Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $27 on, Tuesday, April 30th, 2024
- Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $25 on, Monday, March 25th, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $33 on, Tuesday, March 12th, 2024
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $39 on, Tuesday, March 12th, 2024
